$ cat ./records/awarded-oxitec-5-million-to-develop-self-limiting-genetically-mod-2010.txt
Awarded Oxitec $5 million to develop self-limiting genetically modified Aedes aegypti mosquitoes
[RECORD.TXT] · cat --full
Through the Grand Challenges in Global Health initiative, the Gates Foundation awarded Oxitec $5 million to develop and field-test self-limiting genetically modified Aedes aegypti mosquitoes — the primary vector for dengue fever, Zika, chikungunya, and yellow fever. Oxitec's approach releases lab-bred sterile males carrying a lethal gene: when they mate with wild females, offspring inherit the gene and die before reaching adulthood. Because no chemicals are used and the modification is self-limiting (it disappears from the environment without continued releases), the method offered a precision alternative to broad insecticide spraying in densely populated areas.
Source: https://futurism.com/bill-gates-funded-genehacked-mosquitoes
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Gates Foundation Funds CAVD Global HIV Vaccine Consortia with $287 Million
Next →
Gates Publicly Endorses GMO Crops as Essential to Feeding a Warming World — Defending Intellectual Property as R&D Incentive
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.